Search Results - "HUNNINGHAKE, D. B"

Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication by Elam, NA, Heckman, J, Crouse, J.R, Hunninghake, D.B, Herd, J.A, Davidson, M, Gordon, I.L, Bortey, E.B, Forbes, W.P

“…Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being…”
Get full text

Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial by HOOGWERF, B. J, WANESS, A, KNATTERUD, G. L, WHITE, C, CRESSMAN, M, CANNER, J, CAMPEAU, L, DOMANSKI, M, GELLER, N, HERD, A, HICKEY, A, HUNNINGHAKE, D. B

“…Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary…”
Get full text

Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease : The Heart and Estrogen/progestin Replacement Study by SIMON, Joel A, HUNNINGHAKE, Donald B, AGARWAL, Sanjay K, FENG LIN, CAULEY, Jane A, IRELAND, Christine C, PICKAR, James H

“…Animal and observational epidemiologic studies have reported that estrogens may increase the risk for gallstones. No major clinical trials have examined the…”
Get full text

efficacy of intensive dietary therapy alone or combined with lovastatin in outpatients with hypercholesterolemia by Hunninghake, D.B, Stein, E.A, Dujovne, C.A, Harris, W.S, Feldman, E.B, Miller, V.T, Tobert, J.A, Laskarzewski, P.M, Quiter, E, Held, J

“…Background. A diet low in saturated fat and cholesterol is the standard initial treatment for hypercholesterolemia. However, little quantitative information is…”
Get full text

Recruitment for controlled clinical trials: Literature summary and annotated bibliography by Lovato, Laura C., Hill, Kristin, Hertert, Stephanie, Hunninghake, Donald B., Probstfield, Jeffrey L.

“…This article is a literature summary and annotated bibliography of research on recruitment for controlled clinical trials published through 1995. It extends…”
Get full text

The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day by Davidson, Michael H., Stein, Evan A., Dujovne, Carlos A., Hunninghake, Donald B., Weiss, Stuart R., Knopp, Robert H., Illingworth, D.Roger, Mitchel, Yale B., Melino, Michael R., Zupkis, Robert V., Dobrinska, Michael R., Amin, Raju D., Tobert, Jonathan A.

“…The hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin is the most effective of the currently approved hypolipidemic drugs and has been shown to…”
Get full text

Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels by Kastelein, John J.P, Isaacsohn, Jonathan L, Ose, Leiv, Hunninghake, Donald B, Frohlich, Jiri, Davidson, Michael H, Habib, Rafik, Dujovne, Carlos A, Crouse, John R, Liu, Minzhi, Melino, Michael R, O’Grady, Laura, Mercuri, Michele, Mitchel, Yale B

“…At doses that produced slightly smaller reductions in low-density lipoprotein cholesterol, simvastatin increased high-density lipoprotein cholesterol and…”
Get full text

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial by ROGER ILLINGWORTH, D, GROUSE III, John R, O'GRADY, Laura, MERCURI, Michele, MITCHEL, Yale B, HUNNINGHAKE, Donald B, DAVIDSON, Michael H, ESCOBAR, Ivan D, STALENHOEF, Anton F. H, PARAGH, Gyorgy, MA, Patrick T. S, MINZHI LIU, MELINO, Michael R

“…At higher doses, simvastatin has been shown to produce significantly greater increases in high-density lipoprotein (HDL) cholesterol and apolipoprotein (apo)…”
Get full text

Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care by Hirsch, Alan T, Criqui, Michael H, Treat-Jacobson, Diane, Regensteiner, Judith G, Creager, Mark A, Olin, Jeffrey W, Krook, Susan H, Hunninghake, Donald B, Comerota, Anthony J, Walsh, M. Eileen, McDermott, Mary M, Hiatt, William R

“…CONTEXT Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that is common and is associated with an increased risk of death and…”
Get full text

Effect of Pharmacologic Lipid Lowering on Health-Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study by Santanello, Nancy C., Barber, Beth L., Applegate, William B., Elam, Janet, Curtis, Carolyn, Hunninghake, Donald B., Gordon, David J.

“…OBJECTIVE: To determine the effect of lovastatin therapy on health‐related quality of life in older persons. DESIGN: A prospective, randomized, double blind…”
Get full text

Is aggressive cholesterol control justified? review of the post–coronary artery bypass graft trial by Hunninghake, Donald B

“…The Post–Coronary Artery Bypass Graft (CABG) trial was undertaken to compare the efficacy of aggressive low-density-lipoprotein (LDL) cholesterol lowering (<85…”
Get full text

Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study by Havel, R J, Hunninghake, D B, Illingworth, D R, Lees, R S, Stein, E A, Tobert, J A, Bacon, S R, Bolognese, J A, Frost, P H, Lamkin, G E

“…To evaluate the efficacy and tolerability of lovastatin under controlled conditions in heterozygous familial hypercholesterolemia. Randomized, double-blind,…”
Get more information

Cystatin C Is an Independent Predictor of Fasting and Post-Methionine Load Total Homocysteine Concentrations among Stable Renal Transplant Recipients by Aras, Omer, Tsai, Michael Y, Hanson, Naomi Q, Bailey, Robert, Rao, Gundu, Hunninghake, Donald B

“…An increased prevalence of hyperhomocysteinemia with an increased incidence of cardiovascular disease events has been reported among stable renal transplant…”
Get full text

Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT) by Byington, Robert P., Miller, Michael E., Herrington, David, Riley, Ward, Pitt, Bertram, Furberg, Curt D., Hunninghake, Donald B., Mancini, G.B.John, The Prevent Investigators

“…There is increasing recognition that determinants of plaque rupture leading to overt clinical events more often result from angiographically modest, not…”
Get full text

Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human by Halpin, R A, Ulm, E H, Till, A E, Kari, P H, Vyas, K P, Hunninghake, D B, Duggan, D E

“…Lovastatin is a prodrug lactone whose open-chain 3,5-dihydroxy acid is a potent, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the…”
Get more information

Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia by Davidson, M H, Stein, E A, Hunninghake, D B, Ose, L, Dujovne, C A, Insull, Jr, W, Bertolami, M, Weiss, S R, Kastelein, J J, Scott, R S, Campodónico, S, Escobar, I D, Schrott, H G, Bays, H, Stepanavage, M E, Wu, M, Tate, A C, Melino, M R, Kush, D, Mercuri, M, Mitchel, Y B

“…Clinical data suggesting that larger decreases in low density lipoprotein cholesterol (LDL-C) result in greater reductions in coronary heart disease events…”
Get more information

Pharmacologic management of triglycerides by Hunninghake, Donald B.

“…Currently available cholesterol‐lowering pharmacologic agents have been studied for their effect on reducting triglyceride levels. The fibrates increase…”
Get full text

Drug treatment of dyslipoproteinemia by Hunninghake, D B

“…The bile-acid sequestrants, nicotinic acid and lovastatin, are the most effective drugs for lowering LDL-cholesterol. Nicotinic acid and gemfibrozil are more…”
Get more information

Differences in medical care and disease outcomes among black and white women with heart disease by JHA, Ashish K, VAROSY, Paul D, KANAYA, Alka M, HUNNINGHAKE, Donald B, HLATKY, Mark A, WATERS, David D, FURBERG, Curt D, SHLIPAK, Michael G

“…The risk of cardiovascular mortality is higher among black women than white women, and the reasons for this disparity are largely unexplored. We sought to…”
Get full text

Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy by Yuan, J, Tsai, M Y, Hunninghake, D B

“…The effect of gemfibrozil (GEM) on composition and distribution of LDL subspecies in 10 hypertriglyceridemic (HTG) patients with triglyceride (TG) levels of…”
Get more information